专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明授权

US08759027B2 Production and purification of IL-29 有权
标题翻译：生产和纯化IL-29
公开(公告)号：US08759027B2
公开(公告)日：2014-06-24
申请号：US13720363
申请日：2012-12-19
申请人： ZymoGenetics, Inc.
发明人： Bruce L. Zamost , Geoffrey F. Lee , Robert M. Dedinsky
IPC分类号： C12N15/24 , C12P21/02 , C07K14/54
CPC分类号： C12P21/02 , C07K14/54
摘要： The expression vectors and methods using an E. coli expression system for the large scale production of IL-29 are described. The vectors utilize the IL-29 coding sequence with specific changes in nucleotides in order to optimize codons and mRNA secondary structure for translation in E. coli. Also included are methods of producing, purifying and pegylating an IL-29 polypeptide.
摘要翻译：描述了用于大规模生产IL-29的大肠杆菌表达系统的表达载体和方法。载体利用具有核苷酸特异性变化的IL-29编码序列，以优化用于大肠杆菌翻译的密码子和mRNA二级结构。还包括产生，纯化和聚乙二醇化IL-29多肽的方法。

72. 发明授权

US08748380B2 Albumin variants 有权
标题翻译：白蛋白变体
公开(公告)号：US08748380B2
公开(公告)日：2014-06-10
申请号：US13504326
申请日：2010-11-01
申请人： Andrew Plumridge , Darrell Sleep , Jason Cameron , Inger Sandlie , Jan Terje Andersen , Esben Peter Friis
发明人： Andrew Plumridge , Darrell Sleep , Jason Cameron , Inger Sandlie , Jan Terje Andersen , Esben Peter Friis
IPC分类号： A61K38/38 , A61K47/48 , C07K14/76 , C07K1/00 , C07K14/00 , C07K16/00 , C07K17/00 , C07H21/04 , C12P21/06 , C12P21/04
CPC分类号： C07K14/765 , A61K45/06 , C07K14/54 , C07K2319/20 , C07K2319/31
摘要： The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.
摘要翻译：本发明涉及与母体白蛋白相比具有改变的血浆半衰期的亲本白蛋白的变体。本发明还涉及包含所述变体白蛋白的融合多肽和缀合物。

73. 发明申请

US20140148394A1 COMPOSITIONS AND METHODS FOR MODULATING GAMMA-C-CYTOKINE ACTIVITY 有权
标题翻译：用于调节GAMMA-C细胞因子活性的组合物和方法
公开(公告)号：US20140148394A1
公开(公告)日：2014-05-29
申请号：US13980305
申请日：2012-01-17
申请人： Yutaka Tagaya , Nazli Azimi
发明人： Yutaka Tagaya , Nazli Azimi
IPC分类号： C07K7/08 , C07K7/06
CPC分类号： C07K7/08 , A61K8/64 , A61K38/00 , A61K38/10 , A61K38/20 , A61K47/642 , A61K47/643 , A61Q3/00 , A61Q7/00 , A61Q19/00 , A61Q19/004 , A61Q19/08 , C07K7/06 , C07K14/52 , C07K14/54
摘要： The various embodiments relate to peptide antagonists of γc-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21). The γc-cytokines are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting γc-cytokine activity involve raising neutralizing antibodies against each individual γc-cytokine family member/receptor subunit. However, success has been limited and often multiple γc-cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. Such approach allows for flexibility in antagonist design. In several embodiments, peptides exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members.
摘要翻译：各种实施方案涉及γc家族细胞因子，白细胞介素-2（IL-2），白细胞介素-4（IL-4），白介素-7（IL-7），白细胞介素-9（IL-9），白细胞介素 -15（IL-15）和白细胞介素-21（IL-21）。 γc-细胞因子与重要的人类疾病如白血病，自身免疫疾病，胶原病，糖尿病，皮肤病，退行性神经元疾病和移植物抗宿主病（GvHD）有关。因此，γc-细胞因子活性的抑制剂是有价值的治疗和美容剂以及研究工具。抑制γc-细胞因子活性的传统方法涉及提高针对每个单个γc-细胞因子家族成员/受体亚基的中和抗体。然而，成功是有限的，并且通常多个γc-细胞因子家族成员合作引起疾病状态。组合使用针对每个因素产生的中和抗体是不切实际的，并且造成不良免疫反应的风险增加。本实施例通过利用基于共有γc-亚基结合位点的肽拮抗剂来抑制γc-细胞因子活性来克服这些缺点。这种方法允许拮抗剂设计的灵活性。在几个实施方案中，肽表现出Simul-Block活性，抑制多种γc-细胞因子家族成员的活性。

74. 发明授权

US08735358B2 Methods for treating cancer by regulation of tumor necrosis factor-alpha 有权
标题翻译：通过调节肿瘤坏死因子-α治疗癌症的方法
公开(公告)号：US08735358B2
公开(公告)日：2014-05-27
申请号：US13353840
申请日：2012-01-19
申请人： Soo Hyun Kim , Charles A. Dinarello , Tanya Azam
发明人： Soo Hyun Kim , Charles A. Dinarello , Tanya Azam
IPC分类号： A61K38/20 , A61K9/127 , C07H21/04
CPC分类号： C07K16/244 , A61K38/00 , A61K2039/505 , C07K14/54 , C07K2316/96 , C07K2317/55 , C07K2317/76
摘要： The present invention relates to compositions and methods relating to an interleukin18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (TAIF) or interleukin-32 (IL-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression.
摘要翻译：本发明涉及涉及称为肿瘤坏死因子-α诱导因子（TAIF）或白细胞介素-32（IL-32）的白介素18诱导型细胞因子的组合物和方法。特别地，本发明部分通过调节肿瘤坏死因子-α表达来提供治疗自身免疫性疾病和癌症的组合物和方法。

75. 发明申请

US20140079629A1 Class I Anti-CEA Antibodies and Uses Thereof 有权
公开(公告)号：US20140079629A1
公开(公告)日：2014-03-20
申请号：US14066097
申请日：2013-10-29
申请人： IMMUNOMEDICS, INC.
发明人： Hans J. Hansen , Chien-Hsing Chang , David M. Goldenberg
IPC分类号： A61K47/48 , A61K51/10
CPC分类号： C07K16/3007 , A61K39/39558 , A61K47/55 , A61K47/60 , A61K47/6801 , A61K47/6807 , A61K47/6813 , A61K47/6815 , A61K47/6817 , A61K47/6819 , A61K47/6829 , A61K47/6849 , A61K47/6851 , A61K47/6853 , A61K49/0058 , A61K49/221 , A61K51/088 , A61K51/1027 , A61K51/1093 , A61K51/1096 , A61K2039/505 , A61K2039/545 , C07K14/54 , C07K16/2803 , C07K16/3076 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/515 , C07K2317/53 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C07K2319/00 , C07K2319/30 , A61K2300/00
摘要： The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.

76. 发明申请

US20130344071A1 Class I Anti-CEA Antibodies and Uses Thereof 有权
公开(公告)号：US20130344071A1
公开(公告)日：2013-12-26
申请号：US13898992
申请日：2013-05-21
申请人： Immunomedics, Inc.
发明人： Hans J. Hansen , Chien-Hsing Chang , David M. Goldenberg
IPC分类号： C07K16/30
CPC分类号： C07K16/3007 , A61K39/39558 , A61K47/55 , A61K47/60 , A61K47/6801 , A61K47/6807 , A61K47/6813 , A61K47/6815 , A61K47/6817 , A61K47/6819 , A61K47/6829 , A61K47/6849 , A61K47/6851 , A61K47/6853 , A61K49/0058 , A61K49/221 , A61K51/088 , A61K51/1027 , A61K51/1093 , A61K51/1096 , A61K2039/505 , A61K2039/545 , C07K14/54 , C07K16/2803 , C07K16/3076 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/515 , C07K2317/53 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C07K2319/00 , C07K2319/30 , A61K2300/00
摘要： The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.

77. 发明申请

US20130338067A1 Fusion Polypeptides Comprising an Active Protein Linked to a Mucin-Domain Polypeptide 有权
标题翻译：融合多肽包含与粘蛋白结构域多肽相关的活性蛋白
公开(公告)号：US20130338067A1
公开(公告)日：2013-12-19
申请号：US13911818
申请日：2013-06-06
申请人： ALKERMES, INC.
发明人： JUAN ALVAREZ , JEAN CHAMOUN , HEATHER C. LOSEY
IPC分类号： C07K14/47
CPC分类号： C07K14/55 , A61K38/00 , A61K2039/505 , C07K14/4713 , C07K14/4727 , C07K14/50 , C07K14/54 , C07K14/5412 , C07K14/5443 , C07K14/545 , C07K14/57563 , C07K14/70503 , C07K14/71 , C07K14/7155 , C07K2319/00 , C07K2319/02 , C07K2319/30 , C07K2319/31 , C07K2319/74 , C07K2319/91
摘要： The present invention provides fusion proteins comprising a mucin-domain polypeptide covalently linked to an active protein that has improved properties (e.g. pharmacokinetic and/or physicochemical properties) compared to the same active protein not linked to mucin-domain polypeptide, as well as methods for making and using the fusion proteins of the invention.
摘要翻译：与不与粘蛋白结构域多肽相关的相同活性蛋白质相比，本发明提供了包含与活性蛋白共价连接的粘蛋白结构域多肽的融合蛋白，其具有改善的性质（例如药代动力学和/或物理化学性质），以及制备和使用本发明的融合蛋白。

78. 发明申请

US20130217864A1 HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST - HYBRID FC FUSION PROTEIN 有权
标题翻译：人类白细胞介素-1受体拮抗剂 - 混合融合蛋白
公开(公告)号：US20130217864A1
公开(公告)日：2013-08-22
申请号：US13880175
申请日：2011-10-19
申请人： Young Gyu Cho , Hye Jeong Shin , Woon Young Lee , Woo Ick Jang
发明人： Young Gyu Cho , Hye Jeong Shin , Woon Young Lee , Woo Ick Jang
IPC分类号： C07K16/18 , C07K14/47
CPC分类号： C07K16/18 , C07K14/4705 , C07K14/54 , C07K14/7155 , C07K2319/30
摘要： The present disclosure provides a fusion protein comprising IL-1 receptor antagonist fused to a hybrid Fc. Particularly the present disclosure relates to a fusion protein comprising IL-1 receptor antagonist fused to a human immunoglobulin hybrid Fc fragment. In one embodiment, the hybrid Fc fragment comprises IgD and IgG4. Also provided is a pharmaceutical composition comprising the present fusion protein, which are useful for treating autoimmune disease including rheumatoid arthritis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), psoriasis and diabetes and the like. The present fusion protein with excellent efficacy and reduced side effects is qualified for clinical development as therapeutic antibodies to treat autoimmune disease.
摘要翻译：本公开提供了融合蛋白，其包含与杂交Fc融合的IL-1受体拮抗剂。特别地，本公开涉及融合蛋白，其包含与人免疫球蛋白杂交Fc片段融合的IL-1受体拮抗剂。在一个实施方案中，杂交Fc片段包含IgD和IgG4。还提供了包含本融合蛋白的药物组合物，其可用于治疗包括类风湿性关节炎，炎性肠病（克罗恩病，溃疡性结肠炎），牛皮癣和糖尿病等自身免疫疾病。本发明的融合蛋白具有优异的功效和副作用，减少了治疗自身免疫性疾病的治疗性抗体。

79. 发明申请

US20130172272A1 Novel Polypeptides That Bound to IL-23 Receptor and Inhibit Binding of IL-23 and Cell Signaling Thereof 有权
标题翻译：与IL-23受体结合并抑制IL-23和细胞信号传导的结合的新型多肽
公开(公告)号：US20130172272A1
公开(公告)日：2013-07-04
申请号：US13771305
申请日：2013-02-20
申请人： Grant Gallagher , Raymond Yu , Jonathan Brazaitis
发明人： Grant Gallagher , Raymond Yu , Jonathan Brazaitis
IPC分类号： C07K7/08
CPC分类号： C07K7/08 , A61K38/20 , C07K14/001 , C07K14/54
摘要： The present invention relates to novel polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W,where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. Preferred core structures include WVDYW or WQDYW. The present invention relates a composition containing the novel polypeptides, and use of same in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease.
摘要翻译：本发明涉及结合IL-23受体并抑制IL-23与其相应受体和细胞信号传导的结合的新型多肽。本发明的新型多肽具有WX1X2X3W的核心结构，其中W是色氨酸，X 1，X 2和X 3是氨基酸，条件是当X 1，X 2或X 3中的一个为W时，X 1， X2或X3不能为W.优选的核心结构包括WVDYW或WQDYW。本发明涉及含有新多肽的组合物及其在治疗IL-23相关人类疾病中的应用，包括例如炎症性肠病，牛皮癣和克罗恩病。

80. 发明授权

US08475784B2 IL-21 variants 有权
标题翻译： IL-21变种
公开(公告)号：US08475784B2
公开(公告)日：2013-07-02
申请号：US12447047
申请日：2007-10-26
申请人： Siv Annegrethe Hjorth , Kent Bondensgaard , Dennis Madsen
发明人： Siv Annegrethe Hjorth , Kent Bondensgaard , Dennis Madsen
IPC分类号： A61K38/20
CPC分类号： C07K14/54 , A61K38/20 , A61K45/06 , A61K48/00
摘要： IL-21 variants are provided wherein amino acids have been deleted in the region consisting of amino acid residues no. 65 to 98.
摘要翻译：提供了IL-21变体，其中在由氨基酸残基号组成的区域中已经缺失了氨基酸。 65到98。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式